Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ... ( NEW BRUNSWICK N.J. Nov. 12 /- Senesco...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Date:11/12/2009

NEW BRUNSWICK, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference. Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada. The conference will take place from Sunday, November 15th through Thursday, November 19th, in Boston, MA. Ms. Taylor's abstract will be presented at a session entitled, "Gene Therapies", which will run from 12:30 PM until 2:30 PM on Monday, November 16th.

The conference, hosted by AACR, NCI and EORTC, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. The event has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Senesco Announces H1N1 Influenza Survival Test Results in Mice
2. Senesco Chooses VGXI to Produce Factor 5A Plasmid
3. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
4. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
5. Senesco Technologies Initiates Preclinical Studies for Cancer Target
6. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
7. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
8. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
9. Dr. Julian Henley MD Presents BioMatrix Lift
10. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
11. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. ... analysis systems, announced today that Martin Mulroy ... the Stifel Annual Dental & Veterinary Conference on Wednesday, ... will be held at Le Parker Meridien Hotel in ... About Abaxis Abaxis develops, manufactures, markets and ...

(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ... Changing Regulatory ... the US Market ...

(Date:5/21/2013)... 21, 2013 STAAR Surgical Company (NASDAQ: ... of minimally invasive ophthalmic products, today announced that it ... the Company,s recent financial results and business developments with ... present at the 38 th Annual Deutsche Bank ... at the Westin Waterfront Hotel on Wednesday, May 29, ...

Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4 STAAR Surgical To Present At Upcoming Investor Conferences 2

[0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market [0] STAAR Surgical To Present At Upcoming Investor Conferences

... SHENYANG, China, July 22, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ... a leading China-based biotechnology company focused on researching, developing, ... will release its unaudited second quarter 2011 results after ... 2011 at 8:00pm (US Eastern). Following ...

... Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced ... of the U.S. Food and Drug Administration (FDA) ... treatment of moderately to severely active ulcerative colitis ... inadequate response to conventional therapy. REMICADE® was designated ...

Cached Medicine Technology:3SBio Inc. Schedules Unaudited Second Quarter 2011 Results 2 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 2 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 3 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 4 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 5 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 6 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 7

3SBio Inc. Schedules Unaudited Second Quarter 2011 Results FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis

(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...

(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...

(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...

(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...

Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2 Health News:Research at the cutting edge of knowledge 2 Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2 Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3 Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2

[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis [0] Research at the cutting edge of knowledge [0] Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts [0] Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina

... for diabetes and heart disease, such as high blood ... risk typical of obesity, but they represent only a ... long-term study. The results will be presented Saturday at ... "Some obese persons have a normal cardiovascular risk ...

... ... product line. , ... Germantown, WI (PRWEB) June 19, 2010 -- Ellsworth Adhesives announced today it ... Rapid Seal® line offers high-performance, flexible, chemical resistant sealants that are designed for a ...

... June 2010: Achieving disease remission in patients with ... of socio-economic importance including work productivity and quality ... EULAR 2010, the Annual Congress of the European ... Austrian findings are reported in addition to improvements ...

... ... dedication among healthcare professionals. This awards program salutes the individual health care ... the patients and family members they serve in every sector of the ... Press Club in Washington, D.C., on October 4, where the award winners ...

... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...

... ... Gynecologic Oncologist Mildred Ridgway, MD is now performing a new procedure at Baptist Medical ... Removing uterine fibroids is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, ...

Cached Medicine News:Health News:Certain obese people are not at high risk of heart disease, diabetes 2 Health News:Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering 2 Health News:Targeting disease remission has socio-economic benefits over low disease activity 2 Health News:Targeting disease remission has socio-economic benefits over low disease activity 3 Health News:Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 2 Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2 Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2

Certain obese people are not at high risk of heart disease, diabetes Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering Targeting disease remission has socio-economic benefits over low disease activity Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility

For Dermolipectomy or Lipoplasty of upper arms, Lipoplasty of anterior and lateral axillary folds/rolls...

Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....

Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...

Provides gentle compression above and below implants...

Medicine Products:

Arm Bandage Short-Sleeve Bolero Breast Wrap I Diamond Wear™ Subpectoral Implant Stabilizer